NCT06247995
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06247995
Title A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. (NeoB-Cap1)
Acronym NeoB-Cap1
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | FRA | ESP | DEU | CAN | AUS

Facility Status City State Zip Country Details
UCLA Medical Center Los Angeles California 90095 United States Details
Hoag Memorial Hospital Presbyterian Newport Beach California 92663 United States Details
Mayo Clinic - Rochester Rochester Minnesota 55905 United States Details
Uni Of TX MD Anderson Cancer Cntr Houston Texas 77030 United States Details
University Of Wisconsin Madison Wisconsin 53792 United States Details
Novartis Investigative Site Darlinghurst New South Wales 2010 Australia Details
Novartis Investigative Site Malvern Victoria 3144 Australia Details
Novartis Investigative Site Toronto Ontario M4N 3M5 Canada Details
Novartis Investigative Site Montreal Quebec H3T 1E2 Canada Details
Novartis Investigative Site Tianjin 300300 China Details
Novartis Investigative Site Grenoble 38043 France Details
Novartis Investigative Site Saint-Herblain 44805 France Details
Novartis Investigative Site Villejuif 94800 France Details
Novartis Investigative Site Erlangen 91054 Germany Details
Novartis Investigative Site Tübingen 72076 Germany Details
Novartis Investigative Site Delft South Holland 2625 AD Netherlands Details
Novartis Investigative Site Porto 4200-072 Portugal Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Seoul 03080 South Korea Details
Novartis Investigative Site Seoul 05505 South Korea Details
Novartis Investigative Site L'Hospitalet de Llobregat Barcelona 08907 Spain Details
Novartis Investigative Site Barcelona 08036 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field